Advancements in Pharmacological Obesity Treatments
Received Date: Jul 02, 2025 / Published Date: Jul 30, 2025
Abstract
Recent advances in pharmacological obesity management have delivered highly effective treatments. Dual GIP/GLP-1 receptor agonists like tirzepatide show substantial weight loss and cardiometabolic benefits. GLP-1 receptor agonists such as semaglutide (subcutaneous and oral forms) and liraglutide provide significant weight reduction for adults and adolescents. Combination therapies like naltrexone and bupropion also contribute to effective management. Systematic reviews synthesize evidence on efficacy and safety, while clinical guidelines offer personalized, evidence-based frameworks. Ongoing drug discovery promises further innovative solutions for this complex disease.
Citation: Kim R (2025) Advancements in Pharmacological Obesity Treatments. jowt 15: 825
Copyright: 漏 2025 Rachel Kim This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 257
- [From(publication date): 0-0 - Apr 07, 2026]
- Breakdown by view type
- HTML page views: 189
- PDF downloads: 68
